898 related articles for article (PubMed ID: 29069649)
1. The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis.
Liao W; Zheng H; Wu S; Zhang Y; Wang W; Zhang Z; Zhou C; Wu H; Min J
Am J Nephrol; 2017; 46(5):371-379. PubMed ID: 29069649
[TBL] [Abstract][Full Text] [Related]
2. Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28.
Laurent L; Le Fur A; Bloas RL; Néel M; Mary C; Moreau A; Poirier N; Vanhove B; Fakhouri F
Eur J Immunol; 2017 Aug; 47(8):1368-1376. PubMed ID: 28631301
[TBL] [Abstract][Full Text] [Related]
3. Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice.
Kasagi S; Kawano S; Okazaki T; Honjo T; Morinobu A; Hatachi S; Shimatani K; Tanaka Y; Minato N; Kumagai S
J Immunol; 2010 Mar; 184(5):2337-47. PubMed ID: 20139271
[TBL] [Abstract][Full Text] [Related]
4. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
Enghard P; Langnickel D; Riemekasten G
Scand J Rheumatol; 2006; 35(3):209-16. PubMed ID: 16766368
[TBL] [Abstract][Full Text] [Related]
5. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI
Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427
[TBL] [Abstract][Full Text] [Related]
6. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
Moser K; Kalies K; Szyska M; Humrich JY; Amann K; Manz RA
Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
[TBL] [Abstract][Full Text] [Related]
7. [Expression and clinical significance of PD-L1 on CD14⁺ monocyte in the peripheral blood of patients with systemic lupus erythematosus].
Xie CH; Wang YY; Li ZJ; Tang J; Li BQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Apr; 28(4):429-32. PubMed ID: 22482418
[TBL] [Abstract][Full Text] [Related]
8. B cell apoptosis accelerates the onset of murine lupus.
Trébéden-Nègre H; Weill B; Fournier C; Batteux F
Eur J Immunol; 2003 Jun; 33(6):1603-12. PubMed ID: 12778478
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies from long-lived 'memory' plasma cells of NZB/W mice drive immune complex nephritis.
Cheng Q; Mumtaz IM; Khodadadi L; Radbruch A; Hoyer BF; Hiepe F
Ann Rheum Dis; 2013 Dec; 72(12):2011-7. PubMed ID: 24114925
[TBL] [Abstract][Full Text] [Related]
10. The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice.
Sitrin J; Suto E; Wuster A; Eastham-Anderson J; Kim JM; Austin CD; Lee WP; Behrens TW
J Immunol; 2017 Aug; 199(4):1238-1249. PubMed ID: 28696253
[TBL] [Abstract][Full Text] [Related]
11. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.
Liang B; Gardner DB; Griswold DE; Bugelski PJ; Song XY
Immunology; 2006 Nov; 119(3):296-305. PubMed ID: 17067309
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
14. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice.
Nozaki Y; Yamagata T; Yoo BS; Sugiyama M; Ikoma S; Kinoshita K; Funauchi M; Kanamaru A
Clin Exp Immunol; 2005 Jan; 139(1):74-83. PubMed ID: 15606616
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-Derived Suppressor Cells Induce the Expansion of Regulatory B Cells and Ameliorate Autoimmunity in the Sanroque Mouse Model of Systemic Lupus Erythematosus.
Park MJ; Lee SH; Kim EK; Lee EJ; Park SH; Kwok SK; Cho ML
Arthritis Rheumatol; 2016 Nov; 68(11):2717-2727. PubMed ID: 27214349
[TBL] [Abstract][Full Text] [Related]
16. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential.
Zhao Z; Weinstein E; Tuzova M; Davidson A; Mundel P; Marambio P; Putterman C
Arthritis Rheum; 2005 Feb; 52(2):522-30. PubMed ID: 15693007
[TBL] [Abstract][Full Text] [Related]
17. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
18. Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane.
Summers SA; Odobasic D; Khouri MB; Steinmetz OM; Yang Y; Holdsworth SR; Kitching AR
Clin Exp Immunol; 2014 Jun; 176(3):341-50. PubMed ID: 24528105
[TBL] [Abstract][Full Text] [Related]
19. Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients.
Pavón EJ; Zumaquero E; Rosal-Vela A; Khoo KM; Cerezo-Wallis D; García-Rodríguez S; Carrascal M; Abian J; Graeff R; Callejas-Rubio JL; Ortego-Centeno N; Malavasi F; Zubiaur M; Sancho J
Cytokine; 2013 May; 62(2):232-43. PubMed ID: 23538292
[TBL] [Abstract][Full Text] [Related]
20. Altered IgG autoantibody levels and CD4(+) T cell subsets in lupus-prone Nba2 mice lacking the nuclear progesterone receptor.
Wong AH; Agrawal N; Hughes GC
Autoimmunity; 2015; 48(6):389-401. PubMed ID: 25857203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]